Facebook Twitter YouTube Google Plus

S.) Identifying and Targeting Aggressive Malignant Peritoneal Mesothelioma: Morphologic and Molecular Studies

Alain Borczuk, MD, PhD
Columbia University Medical Center

Dr. Alain Borczuk is a Professor of Clinical Pathology at Columbia University Medical Center in New York.  A graduate of Princeton University and Cornell University Medical School, he is currently a surgical pathologist specializing in lung pathology and collaborates extensively with the team of physicians in the Mesothelioma Center at Columbia, including Drs. Taub and Chabot.  As a result, he reviews the pathology on numerous peritoneal mesothelioma. His research interests include classification of lung cancer and mesothelioma using modern molecular techniques. In mesothelioma, his work has focused on pathways of aggressive tumor behavior in peritoneal malignant mesothelioma.


Click here to view the slides for "Identifying and Targeting Aggressive Malignant Peritoneal Mesothelioma: Morphologic and Molecular Studies", by Alain Borczuk, MD, PhD.

To view this video presentation, please click on the below image.

© 2009 Mesothelioma Applied Research Foundation, Inc. All rights reserved. 501(c)(3)

A.) Effective Advocacy and the Case for Federal Meso Research Funding

B.) State Assistance on Insurance Appeals

C.) Cancer Genetics in the Mesothelioma Family

D.) Fundraising

E.) Navigating Mesothelioma Clinical Trials with GPS (Getting Personalized Service)

F.) Update from Across the Pond

G.) The Mesothelioma Experience: Patient and Provider Perspectives Panel

H.) Work of the Science Advisory Board

J.) Present and Future of Mesothelioma Treatment: Medical Oncologist and Researcher Perspective

K.) New Developments in Radiation Oncology: A Global Perspective

M.) Pain Management

Mesothelioma Treatment: Present & Future from a Surgeon & Research Perspective | Dr. Harvey Pass

N.) Traditional Healing with Modern Science

O.) Update on Clinical Trials and Mesothelioma Research

P.) Mesothelioma Tissue Bank

Photodynamic Therapy for Mesothelioma Treatment | Dr. Joseph Friedberg

Q.) EGFR Inhibitors for Patients with Malignant Peritoneal Mesothelioma

R.) The Use of Cytokine Inhibitors: Translational Lab Results

S.) Identifying and Targeting Aggressive Malignant Peritoneal Mesothelioma: Morphologic and Molecular Studies

T.) Treatment Options for Patients with Recurrent Disease after HIPEC, HRA - Panel Discussion